MELBOURNE, AUSTRALIA--(Marketwired - July 01, 2013) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) announces that a record number of BREVAGen™ test samples were received during the quarter ended June 30, 2013. Total patient samples received during the quarter was 599, representing growth of more than 48% over the preceding March quarter, demonstrating a significant increasing trend in market traction.
Total BREVAGen™ test samples received during the 2013 financial year was 1,547, representing growth of more than 272% over the preceding 2012 financial year.
Encouragingly, the quarter on quarter percentage growth in the number of BREVAGen™ samples received has been progressively increasing in each of the eight completed quarters since the test was launched in the U.S. market in July 2011. Further, the samples currently being received are generated from a broad mix of U.S. geographical sales territories, demonstrating the growing acceptance of the test across the wider market.
About Genetic Technologies Limited
Genetic Technologies was an early pioneer in recognizing important new applications for "non-coding" DNA (Deoxyribonucleic Acid). The Company has since been granted patents in 24 countries around the world, securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all species. Its business strategy is the global commercialization of its patents through an active out-licensing program and the global expansion of its oncology and cancer management diagnostics portfolio. Genetic Technologies is an ASX and NASDAQ listed company with operations in the USA and Australia. For more information, please visit www.gtglabs.com.
Safe Harbor Statement
Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.